The cancer drug company Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has had its fair share of disappointments with its approved leukemia drug, Iclusig. From market suspension to halting of the study of the drug in newly-diagnosed patients, Ariad has seen it all but the company looks unbowed. Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) weekly performance is 10.16%. On last trading day company shares ended up $6.94. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc (NASDAQ:ARIA distance from 50-day simple moving average (SMA50) is -3.79%.
Baupost Group grew its portfolio of U.S. stocks by17 percent to $4.14 billion in the first quarter, maintaining large positions in several companies, including Cambridge-based Idenix Pharmaceuticals Inc (NASDAQ:IDIX). Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was 6.06% in last session and finished the day at $6.03. Traded volume was 789,231 shares in the last session and the average volume of the stock remained 1.29 million shares. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares advanced 10.05% in last trading session and ended the day on $6.90. Its return on assets is -120.10%. Quarterly performance is 3.14%.
Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp (NYSE:XON) stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) stock performance was 12.84% in last session and finished the day at $17.49. Traded volume was 1.93million shares in the last session and the average volume of the stock remained 845.13K shares. Intrexon Corp (NYSE:XON) insider ownership is 0.30%. Intrexon Corp (NYSE:XON) shares moved up 5.64% in last trading session and was closed at $22.28, while trading in range of $21.38-22.50.Year to date (YTD) performance is-6.39 %.
On June 2, Albany Molecular Research, Inc. (NASDAQ: AMRI) announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC (“OsoBio”) for $110 million in cash. OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquisition and associated fees are expected to be financed through cash currently held by AMRI, and, subject to Hart-Scott-Rodino clearance and other conditions to closing, is expected to be completed in the third quarter of 2014.Albany Molecular Research,Inc (NASDAQ:AMRI)ended the last trading day at $16.84. Company weekly volatility is calculated as 4.04% and price to cash ratio 3.27. Albany Molecular Research, Inc (NASDAQ:AMRI showed a positive weekly performance of 5.91%.
On May 27, It emerged over the last weekend that, The Dow Chemical Company (NYSE:DOW) through its subsidiary Dow Agro sciences has signed up with Sigma-Aldrich Corporation (NASDAQ:SIAL) on a new frame work agreement which covers areas of manufacturing and supply chain of chemical reagent zinc finger nuclease. As per the terms of the agreement, the St Louis based firm will manufacture the chemical under license by using the patented EXZACT Precision Technology which will be used by The Dow Chemical Company (NYSE:DOW) in their “seeds and traits pipeline”. Neither of the two firms disclosed the financial terms of the agreement. Sigma-Aldrich Corporation (NASDAQ:SIAL) weekly performance is21.63 %. On last trading day company shares ended up $99.06. Distance from 50-day simple moving average (SMA50) is 20.89 %.